Keyholder Funding Cancer Breakthrough Portfolio
A portfolio of investments focused on the development of new, disruptive treatments, diagnostics and drugs, all of which could dramatically improve the way cancer is treated.
Diatech MICK – Diagnostics to accurately identify the most effective chemotherapy treatments.
Vaccicure – Prevents the growth of cancers by removing the hormone that feeds them.
Two other products will be launched within Q3 2018.
Please view an introduction to Keyholder Funding Cancer Breakthrough Portfolio here.
An investment summary on Keyholder Funding can be viewed here.